Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices

Latest News

February 26, 2020: Maimon launches a pre-publication and review series of reports: Maimon Working Papers. These summarize the latest studies by Maimon Research on health technology assessment and claims for cost-effectiveness, pricing and access.

 

The purpose of the Maimon Working Paper series is to critically assess ongoing reports by groups such as the Institute for Clinical and Economic Review (ICER) that make recommendation for cost-effectiveness, pricing and product access that fail to meet the standards of normal science. These standards, which have been in place since the 17th century, see the progress in science as one of the discovery of new facts.

 

ICER sees the future of technology assessment in the recycling of old facts. The fabrication of assumption driven lifetime imaginary worlds to support incremental cost-per-QALY claims. This is an absurd position; made even more absurd when the fabricated construct fails to appreciate the axioms of fundamental measurement in creating meaningless QALY metrics. 

Print Print | Sitemap
© Maimon Research LLC